Can Fite Biopharma Ltd (CANF) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.568x

Based on the latest financial reports, Can Fite Biopharma Ltd (CANF) has a cash flow conversion efficiency ratio of -0.568x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-2.38 Million ≈ $-6.37K USD) by net assets (ILA4.18 Million ≈ $11.22K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CANF equity financing ratio to measure how much of total assets are equity-financed.

Can Fite Biopharma Ltd - Cash Flow Conversion Efficiency Trend (2010–2025)

This chart illustrates how Can Fite Biopharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CANF cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Can Fite Biopharma Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Can Fite Biopharma Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
MEKICS Co Ltd KQ:058110	-0.012x
JW Pharmaceutical Corp KO:001067	0.132x
Indal Aluminium Industry Tbk JK:INAI	0.399x
Signature Resources Ltd V:SGU	2.752x
Mangoceuticals, Inc. Common Stock NASDAQ:MGRX	-0.079x
Safello Group AB ST:SFL	-0.015x
SC Estate Builder Bhd KLSE:0109	-0.098x
PLAYWITH Inc KQ:023770	-0.027x

Annual Cash Flow Conversion Efficiency for Can Fite Biopharma Ltd (2010–2025)

The table below shows the annual cash flow conversion efficiency of Can Fite Biopharma Ltd from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Can Fite Biopharma Ltd worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	ILA5.59 Million ≈ $15.00K	ILA-9.69 Million ≈ $-25.97K	-1.732x	-23.28%
2024-12-31	ILA5.44 Million ≈ $14.57K	ILA-7.64 Million ≈ $-20.47K	-1.405x	-3.92%
2023-12-31	ILA6.24 Million ≈ $16.74K	ILA-8.44 Million ≈ $-22.63K	-1.352x	+44.03%
2022-12-31	ILA4.47 Million ≈ $11.99K	ILA-10.80 Million ≈ $-28.96K	-2.415x	-252.36%
2021-12-31	ILA14.38 Million ≈ $38.56K	ILA-9.86 Million ≈ $-26.43K	-0.685x	+65.49%
2020-12-31	ILA6.07 Million ≈ $16.28K	ILA-12.06 Million ≈ $-32.34K	-1.986x	+55.24%
2019-12-31	ILA2.44 Million ≈ $6.55K	ILA-10.83 Million ≈ $-29.05K	-4.437x	-221.93%
2018-12-31	ILA3.02 Million ≈ $8.08K	ILA-4.16 Million ≈ $-11.14K	-1.378x	+55.81%
2017-12-31	ILA3.05 Million ≈ $8.19K	ILA-9.52 Million ≈ $-25.53K	-3.118x	-35.33%
2016-12-31	ILA3.87 Million ≈ $10.39K	ILA-8.93 Million ≈ $-23.93K	-2.304x	-417.41%
2015-12-31	ILA10.44 Million ≈ $28.00K	ILA-4.65 Million ≈ $-12.47K	-0.445x	+58.32%
2014-12-31	ILA6.86 Million ≈ $18.38K	ILA-7.33 Million ≈ $-19.64K	-1.069x	+44.80%
2013-12-31	ILA4.46 Million ≈ $11.95K	ILA-8.63 Million ≈ $-23.14K	-1.936x	-131.52%
2012-12-31	ILA-707.99K ≈ $-1.90K	ILA-4.35 Million ≈ $-11.66K	6.141x	+467.80%
2011-12-31	ILA3.29 Million ≈ $8.82K	ILA-5.50 Million ≈ $-14.73K	-1.670x	-497.22%
2010-12-31	ILA13.07 Million ≈ $35.05K	ILA-3.65 Million ≈ $-9.80K	-0.280x	--

About Can Fite Biopharma Ltd

TA:CANF Israel Biotechnology

Market Cap

$6.08 Million

ILA2.27 Billion ILA

Market Cap Rank

#28187 Global

#409 in Israel

Share Price

ILA529.00

Change (1 day)

+6.22%

52-Week Range

ILA1.00 - ILA1500.00

All Time High

ILA1500.00